SYRE
Price
$12.74
Change
-$1.25 (-8.93%)
Updated
Apr 4, 04:13 PM (EDT)
Capitalization
933.38M
34 days until earnings call
XBIO
Price
$2.46
Change
-$0.13 (-5.02%)
Updated
Apr 4, 04:25 PM (EDT)
Capitalization
3.99M
Ad is loading...

SYRE vs XBIO

Header iconSYRE vs XBIO Comparison
Open Charts SYRE vs XBIOBanner chart's image
Spyre Therapeutics
Price$12.74
Change-$1.25 (-8.93%)
Volume$528
Capitalization933.38M
Xenetic Biosciences
Price$2.46
Change-$0.13 (-5.02%)
Volume$350
Capitalization3.99M
SYRE vs XBIO Comparison Chart
Loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRE vs. XBIO commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Hold and XBIO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (SYRE: $13.99 vs. XBIO: $2.59)
Brand notoriety: SYRE and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 147% vs. XBIO: 52%
Market capitalization -- SYRE: $933.38M vs. XBIO: $3.99M
SYRE [@Biotechnology] is valued at $933.38M. XBIO’s [@Biotechnology] market capitalization is $3.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 3 bullish TA indicator(s).

  • SYRE’s TA Score: 4 bullish, 4 bearish.
  • XBIO’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than XBIO.

Price Growth

SYRE (@Biotechnology) experienced а -20.92% price change this week, while XBIO (@Biotechnology) price change was -20.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.17%. For the same industry, the average monthly price growth was -17.02%, and the average quarterly price growth was -18.73%.

Reported Earning Dates

SYRE is expected to report earnings on May 08, 2025.

XBIO is expected to report earnings on Aug 11, 2023.

Industries' Descriptions

@Biotechnology (-11.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($933M) has a higher market cap than XBIO($3.99M). XBIO YTD gains are higher at: -35.088 vs. SYRE (-39.906). XBIO has higher annual earnings (EBITDA): -4.36M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. XBIO (6.84M). SYRE has less debt than XBIO: SYRE (0) vs XBIO (153K). XBIO has higher revenues than SYRE: XBIO (2.52M) vs SYRE (0).
SYREXBIOSYRE / XBIO
Capitalization933M3.99M23,360%
EBITDA-208.57M-4.36M4,783%
Gain YTD-39.906-35.088114%
P/E Ratio1.72N/A-
Revenue02.52M-
Total Cash603M6.84M8,816%
Total Debt0153K-
FUNDAMENTALS RATINGS
SYRE vs XBIO: Fundamental Ratings
SYRE
XBIO
OUTLOOK RATING
1..100
351
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
9093
P/E GROWTH RATING
1..100
75100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (17) in the Biotechnology industry is somewhat better than the same rating for SYRE (77) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew somewhat faster than SYRE’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to SYRE’s over the last 12 months.

XBIO's SMR Rating (97) in the Biotechnology industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (90) in the Pharmaceuticals Major industry is in the same range as XBIO (93) in the Biotechnology industry. This means that SYRE’s stock grew similarly to XBIO’s over the last 12 months.

SYRE's P/E Growth Rating (75) in the Pharmaceuticals Major industry is in the same range as XBIO (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREXBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMIEX14.27N/A
N/A
MM S&P 500® Index Svc
RRCOX55.42N/A
N/A
T. Rowe Price U.S. Equity Research R
IJMAX15.15N/A
N/A
VY® JPMorgan Mid Cap Value A
HWSCX51.47N/A
N/A
Hotchkis & Wiley Small Cap Value C
IICHX10.80N/A
N/A
AMF Large Cap Equity H